INTRODUCTION AND OBJECTIVES:
BCa is a heterogeneous disease: non-muscle-invasive bladder cancer (NMIBC) that usually recur but rarely process, and muscle-invasive bladder cancer (MIBC) that progress quickly. Recent studies identify numerous clinical variables and molecular biomarkers, such as chromosomal markers, genetic variations or epigenetic alterations for prediction of its occurrence and recurrence. However, effective biomarkers to distinguish MIBC from NMIBC are urgently needed. Transmembrane-4-L-Six-Family-1 (TM4SF1) is a member of L6 family, which functions as signal transducer to regulate cell development, growth and motility. The aim of the study is to investigate the TM4SF1 as the specific biomarker of MIBC via bioinformatics analysis.
METHODS: Through mining the big data from GEO and TCGA, a specific MIBC differentially expressed gene (DEG) called TM4SF1 was screened by R and validated by oncomine database, etc. Then qRT-PCR, immunofluorescence and immunohistochemistry analysis were used to detect the transcription and translation level of TM4SF1 in bladder tissues. Clinical correlation was measured by connecting the expression of TM4SF1 with patients 0 information. Moreover, TM4SF1 knockdown and overexpression BCa cell model was established by gene regulation. Then flow cytometry, CCK-8 assay, western blot, etc. were used to detect cell cycle distribution, cell growth and related protein expression in vitro. Furthermore, the xenograft model was used to measure the tumor growth of BCa cells transplantation in vivo.
RESULTS: Our results suggested that TM4SF1 was strongly upregulated in MIBC tissues, corroborated with transcriptome analysis. Moreover, tissue microarray (TMA) showed significant correlations between TM4SF1 with T stage, TNM stage, lymph node metastasis status and survival rate of MIBC patient. Furthermore, in vitro and in vivo studies suggested that proliferation of human bladder cancer (BCa) cells was significantly suppressed by downregulated TM4SF1. Functionally, reduction of TM4SF1 could induce cell cycle arrest and apoptosis possibly via upregulation of reactive oxygen species (ROS) in the BCa cells. Interestingly, these observations were scavenged by treatment of GW9662 (antagonist of PPARg) and resveratrol (activator of SIRT1), respectively. CONCLUSIONS: We have first shown tumor promoting effect of TM4SF1 on MIBC. TM4SF1 could be a biomarker to predict the survival rate of MIBC patients and malignancy of the tumor. And our study suggest that the regulation of ROS metabolism and cell cycle for TM4SF1 in BCa cells was mediated by PPARg-SIRT1 feedback loop. To evaluate the hypothesis that muscarinic acetylcholine receptors may play a role in bladder cancer as well as in other tumor types, we investigated their expression in bladder tumor specimens.
METHODS: Human bladder cancer 5637, T24 and HT1197 cell lines (grade 2, 3, 4; respectively) were purchased from Cell Lines Service (CLS Eppelheim, Germany) and ICLC (ICLC, Genova, Italy), respectively. Bladder cancer tissue was obtained from a total of 16 patients underwent to surgical treatment (8 with non-muscle invasive low and 8 with high grade of TCC). Four urothelial samples, obtained from patients underwent bladder biopsy for diseases other than bladder tumor (all selected cases suffering from ureteral lithiasis) were used as controls. M2 receptor expression has been measured by quantitative PCR, immunofluorescence and immunohistochemistry. Arecaidine (M2 receptor agonist)-treated and control cells were compared for changes in the growth pattern, survival and migration properties.
RESULTS: All examined samples expressed the M1, M2 and M3 receptor subtypes. We also found that the level of M2 transcripts, but not those of M1 or M3, significantly increased with the tumor histologic grade. In view of these results, we proceeded to investigate whether the M2 agonist Arecaidine had any effect on in vitro cell growth and migration of T24 cells, a bladder tumor cell line expressing the muscarinic receptors, including the M2 subtype. We observed that Arecaidine significantly reduced T24 and 5637 cell proliferation and migration in a concentration dependent manner. The silencing of M2 receptor by siRNA in T24 and 5637 cell lines showed the inability of Arecaidine (100 mM) to inhibit cell proliferation after 48 hours, whereas the use of M1 and M3 antagonists in T24 appeared not to counteract the Arecaidine effect, suggesting that the inhibition of cell proliferation was directly dependent on M2 receptor activation.
CONCLUSIONS: For the first time we show that M2 is upregulated in high grade urothelial bladder cancer specimens and that its agonistic stimulation affect both in vitro proliferation and migration of urothelial cancer cell line. We believe that our data could help to clarify the role of the M2 muscarinic receptors in urothelial bladder cancer. These data suggest that M2 muscarinic receptors may play a relevant role in bladder cancer and represent a new attractive therapeutic target. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e715
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MP54-11 IDENTIFICATION AND REPLICATION OF THE INTERPLAY OF FOUR GENETIC HIGH-RISK VARIANTS FOR URINARY BLADDER CANCER
INTRODUCTION AND OBJECTIVES: Genome-wide association studies identified or confirmed 15 genomic regions that modulate urinary bladder cancer risk. Little is known whether these genetic variants interact to increase bladder cancer risk. Furthermore, it is likely that different polymorphisms are relevant in smokers and non-smokers. Therefore, we conducted an interaction analysis comprising 12 susceptibility variants and totally 5049 cases and 5452 controls.
METHODS: Recently, we identified two-and three-variant combinations associated with a particular increase of bladder cancer risk in a urinary bladder cancer case-control series (Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), 1501 cases, 1565 controls). In an independent case-control series (Nijmegen Bladder Cancer Study, NBCS, 1468 cases, 1720 controls) we confirmed these two-and three-variant combinations. Pooled analysis of the two studies as discovery group (IfADo-NBCS) resulted in sufficient statistical power to test up to four-variant combinations by a logistic regression approach. The New England and Spanish Bladder Cancer Studies (2080 cases and 2167 controls) were used as a replication series. Twelve previously identified risk variants were considered.
RESULTS: The strongest four-variant combination was obtained in never smokers. The combination of rs1014971[AA] near apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) and chromobox homolog 6 (CBX6), solute carrier family 1s4 (urea transporter), member 1 (Kidd blood group) (SLC14A1) exon single nucleotide polymorphism (SNP) rs1058396 [AG, GG] , UDP glucuronosyltransferase 1 family, polypeptide A complex locus (UGT1A) intron SNP rs11892031[AA] and rs8102137[CC, CT] near cyclin E1 (CCNE1) resulted in an unadjusted odds ratio (OR) of 2.59 (95% CI ¼ 1.93-3.47; P ¼ 1.87 x 10 -10 , while the individual variant ORs ranged only between 1.11 and 1.30. The combination replicated in the New England and Spanish Bladder Cancer Studies (OR unadjusted ¼ 1.60, 95% CI ¼ 1.10-2.33; P ¼ 0.013). The four-variant combination is relatively frequent, with 25% in never smoking cases and 11% in never smoking controls (total study group: 19% cases, 14% controls).
CONCLUSIONS: In conclusion, we show that four high-risk variants can statistically interact to confer increased bladder cancer risk particularly in never smokers. 
MP54-12 MOLECULAR CHARACTERIZATION OF N-METHYL-N-NITROSOUREA-INDUCED BLADDER UROTHELIAL TUMOR IN RATS
Takahiro Yoshida*, Alexander Baras, Max Kates, Nikolai Sopko, Xiaopu Liu, Gregory Joice, David McConkey, Trinity Bivalacqua, Baltimore, MD INTRODUCTION AND OBJECTIVES: Human bladder cancer has recently been characterized based on RNA/protein expression and genomic alterations, indicating intrinsic subtypes of the disease associated with prognosis and response to systemic therapy. Meanwhile, Nmethyl-N-nitrosourea (MNU)-induced bladder tumor in rodents are widely used for study of human bladder cancer. Although the model mimics papillary morphology and step-wise progression of human bladder cancer, little is known about molecular similarities to human bladder cancer. In this study, we characterized MNU-induce bladder tumor in rats using immunohistochemistry, qRT-PCR, and RNA sequencing.
METHODS: Fisher 344 rats at age of 7 weeks intravesically received 4 doses of 1.5mg/kg MNU. Animals were sacrificed at week 16 and 30, and bladders were processed for pathological evaluation. RNA was also extracted from normal urothelium and cancerous area in paraffin embedded tissue, and subjected to qRT-PCR and RNA sequencing. Sequencing data was analyzed with publicly available dataset of human bladder cancer.
RESULTS: At week 16, all rats were found to have non-muscle invasive bladder tumor. Rats developed 5-10-mm, protruding tumors in their bladders at week 30. H&E staining showed MNU-induced tumors were histologically similar to human papillary bladder tumors. Three out of 6 bladders at week 30 showed muscle invasion. Immunohistochemistry and qRT-PCR revealed enrichment of basal markers in MNU tumors compared to normal urothelium, while maintaining luminal markers. Analysis of sequencing data showed that MNU tumors were clustered with human luminal tumors with upregulation of FGFR3 signature.
CONCLUSIONS: Combination of immunohistochemistry, qRT-PCR, and RNA sequencing demonstrated that MNU-induced tumor was closely related to the luminal/UroB tumor subtype of human bladder cancer. MNU-induced bladder tumor in rats offers a good experimental platform that mimics a subset of human bladder cancer in immunocompetent environment.
